Nomad Bioscience and Icon Genetics sign broad cross-license agreement

Munich, March 15, 2012 — NOMAD Bio­science GmbH, Munich, Ger­many (NOMAD) and its whol­ly owned sub­sidiary Icon Genet­ics GmbH, Munich, Ger­many (ICON) have entered into a broad cross-licens­ing agree­ment.

NOMAD has acquired ICON from Bay­er Inno­va­tion GmbH on Decem­ber 31, 2011. Dur­ing 1999–2012 since its incor­po­ra­tion, ICON has devel­oped a num­ber of plant-based man­u­fac­tur­ing tech­nolo­gies. Many of the tech­nolo­gies are rely­ing on tran­sient expres­sion in green plants. Dur­ing the time since its incep­tion (2008), NOMAD has devel­oped new tech­nolo­gies that also take advan­tage of tran­sient expres­sion in plants.

Both NOMAD and ICON con­tin­ue active research and devel­op­ment efforts around essen­tial­ly sim­i­lar man­u­fac­tur­ing plat­form, and there is a lot of poten­tial syn­er­gy in com­bin­ing their exist­ing tech­nol­o­gy solu­tions, as well as join­ing their future research efforts.

At the same time, the two com­pa­nies ser­vice dif­fer­ent mar­kets. Where­as ICON pur­sues bio­phar­ma­ceu­ti­cals and ani­mal health pro­teins mar­kets, NOMAD has posi­tioned itself in the areas of agro­nom­ic traits, bio­ma­te­ri­als, bioen­er­gy and food safe­ty.

Effec­tive March 15, the two com­pa­nies have agreed to license each oth­er in their respec­tive mar­ket areas. The cross licens­ing deal includes their past intel­lec­tu­al prop­er­ty rights (to the extent allowed by oth­er ear­li­er com­mit­ments of the two com­pa­nies), as well as future inven­tions. The mate­r­i­al aspects of the cross-licens­ing agree­ment have not been dis­closed.

Prof. Dr. Yuri Gle­ba, CEO and founder of NOMAD and co-founder of ICON, said: ”The deal cre­ates a pow­er­ful IP port­fo­lio of more than 50 patent fam­i­lies includ­ing over 380 issued patents that rivals the port­fo­lios of major plant biotech com­pa­nies. It is by far the best IP con­trol pack­age in the area of tran­sient expres­sion in plants. Both NOMAD and ICON will enjoy mul­ti­ple ben­e­fits from this joint exploita­tion of their IP, and they will cer­tain­ly be able to pur­sue their respec­tive busi­ness mar­kets more aggres­sive­ly.”

About NOMAD:
NOMAD is a pri­vate biotech­nol­o­gy com­pa­ny devel­op­ing agro­nom­ic traits and plant-made bio­ma­te­ri­als that address crit­i­cal unmet needs. NOMAD’s pro­pri­etary tech­nolo­gies fur­ther improve the upstream part of the man­u­fac­tur­ing process, but they also pro­vide for nov­el down­stream solu­tions that togeth­er with the pro­pri­etary and in-licensed upstream com­po­nents result in a ful­ly inte­grat­ed man­u­fac­tur­ing process for most of NOMAD’s intend­ed prod­ucts. NOMAD’s agro­nom­ic trait pipeline is being devel­oped joint­ly with a major part­ner. NOMAD’s bio­ma­te­r­i­al pipeline con­sists of sev­er­al select­ed prod­uct can­di­dates, includ­ing plant-made cel­lu­lase enzymes (expect­ed impact: up to 30 per­cent low­er man­u­fac­tur­ing cost of bioethanol), and antimi­cro­bial pro­teins, includ­ing col­icins, lysins and bac­te­ri­ocins (unmet needs in food safe­ty and ani­mal health).

About ICON:
ICON is a whol­ly owned sub­sidiary of NOMAD. The Com­pa­ny dis­cov­ers and devel­ops new bio­phar­ma­ceu­ti­cals and high-val­ue pro­tein prod­ucts using green plants as pro­duc­tion hosts. ICON offers new plant man­u­fac­tur­ing tech­nolo­gies which address speed, yield, pre­ci­sion, expres­sion con­trol and safe­ty of prod­uct man­u­fac­tur­ing in plants. ICON oper­ates its own cGMP-com­pli­ant man­u­fac­tur­ing facil­i­ty in Halle, Ger­many. ICON’s pipeline includes prod­ucts devel­oped for Bay­er Inno­va­tion (indi­vid­u­al­ized anti-can­cer vac­cine for Non-Hodgkin’s Lym­phoma, cur­rent­ly in Phase I clin­i­cal tri­als) as well as sev­er­al ‘bio­bet­ter’ anti-can­cer anti­bod­ies (pre-clin­i­cal stage).